DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Santaris Pharma
Santaris Pharma
Santaris Pharma A/S Advances a Second Drug from Its
Advances in Oligonucleotide Drug Delivery
Antiviral Research 111 (2014) 53–59
Brevpapir, Kun Dansk Adresse
Santaris Pharma A/S Announces an Expanded Worldwide Strategic
Understanding Life Science Partnership Structures
Santaris Pharma A/S Phase 2A Data of Miravirsen Shows Dose-Dependent
Locked Nucleic Acid: Modality, Diversity, and Drug Discovery
Mcdermott Will & Emery Llp William G. Gaede
RNA-Based Therapeutics: from Antisense Oligonucleotides to Mirnas
Miragen Snares Servier in Rousing Microrna Deal
Rnai Therapeutics
Santaris Pharma A/S Advances Miravirsen, the First Microrna-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected with Hepatitis C Virus
Tiny LNA-Based Compounds Inhibit Entire Disease-Associated Microrna Families 20 March 2011
Short Locked Nucleic Acid Antisense Oligonucleotides Potently Reduce
Glaxo Deal Shows Antisense Starting to Make Sense for Pharma
Anti-Viral Proof of Concept Study of Miravirsen, an Oligonucleotide Targeting Mir-122, in Treatment of Naïve Patients with Genotype 1 Chronic HCV Infection
Therapeutic Targeting of Micrornas: Current Status and Future Challenges
Top View
Development of Antisense Drugs for Dyslipidemia
Mir-122–Based Therapies Select for Three Distinct Resistance Mechanisms Based on Alterations in RNA Structure
Microrna Silencing in Primates: Towards Development of Novel Therapeutics Andreas Petri,1 Morten Lindow,1 and Sakari Kauppinen1,2
Locked Nucleic Acid Oligonucleotides Toward Clinical Applications
Evaluation of Proprotein Convertase Subtilisin/Kexin Type 9: Focus on Potential Clinical and Therapeutic Implications for Low-Density Lipoprotein Cholesterol Lowering
Santaris Pharma A/S Phase 2A Data of Miravirsen Shows Dose-Dependent
How Close Are Mirnas from Clinical Practice?
RNA-Bound: the Future of Antisense Drugs ➜ Keith Mccullagh*